- Basic science cancer research pilot projects
- Translational cancer research pilot projects
- What is ITRAC?
Basic science cancer research pilot projects
Funding will be allocated from the IU Simon Cancer Center, using the ITRAC mechanism/process, and will be allocated based on need up to $50,000. We are particularly interested in receiving applications from investigators who, with this additional support, are likely to obtain extramural peer-reviewed funding. Projects with inter-programmatic collaborative teams are encouraged. Successful applicants can request additional funds after completion of their current milestone for further project development. Applicants may have received prior or current extramural research funding, but the proposed project should be separate from previous or current funded projects.
Resources available to investigators include access to the IU Simon Cancer Center translational coordinators for “mapping.” The mapping process will also involve a determination of the amount of funds required for each process/benchmark such that funds will be given out as necessary to move the project to the next benchmark/process or milestone. To schedule the project mapping, which must be completed prior to the application submission date, contact Crystal Banks (crybanks@iupui.edu) and/or Mary Murray (memurray@iupui.edu). For further details of ITRAC, contact Mark Kelley (mkelley@iupui.edu).
Deadlines for mapping requests must be scheduled by:
For spring review: March 1, 2011
For fall review: Aug. 1, 2011
Final applications are due by April 8, 2011, and Sept. 2, 2011
The body of the proposal should not exceed three pages plus one page for Aims and should address the translational nature and future clinical application of the project, as well as include the project map/budget. Proposals need to follow NIH formatting guidelines of fonts of Helvetica or Arial, font size 11 points or larger, and ½-inch margins. A budget will be generated during the mapping process. Proposals should not include percent effort (salary) for the principal investigator. An electronic copy in PDF format should be submitted and should include:
- Abstract (NIH format; 30 lines)
- Aims (1 page)
- Significance
- Innovation
- Approach
- Project map
- NIH biosketch
The Significance, Innovation, and Approach sections should not exceed three pages. Aims page can be up to one page. Abstract should be standard NIH format length (30 lines). Applications will be reviewed by the IUSCC Leadership Council and additional expert reviewers as necessary. Final funding decisions will be made by the IUSCC Executive Committee based on the review evaluations and rankings.
Criteria for review:
- Scientific merit
- Cancer relatedness
- Evidence of multidisciplinary approach
- Potential for translation
- Potential for subsequent peer reviewed funding
What is the timetable?
For spring review
- Mapping request before or by March 1, 2011
- Completed application (must include completed map): April 8, 2011
- Funding start date: June 1, 2011
For fall review
- Mapping request before or by Aug. 1, 2011
- Completed application (must include completed map): Sept. 2, 2011
- Funding start date: Nov. 1, 2011
Applications should be sent to:
Elizabeth Parsons
Grants Coordinator
278-0078
Translational cancer research pilot projects
IU Simon Cancer Center is inviting pilot feasibility proposals for cancer research projects in the areas of translational chemical biology and drug discovery. Funding is scheduled to begin on May 1, 2011. A primary goal of the IU Simon Cancer is to stimulate multi-disciplinary and translational research. The latter is research that seeks to develop and translate laboratory observations to innovative clinical trials. The purpose of this EDT-specific RFA is to promote intra- and inter-programmatic collaboration for the development of small molecule therapeutics against new cancer targets identified by IUSCC members. The duration of funding is one year and the budget should not exceed $50,000. Applicants must be IU Simon Cancer Center full or associate members and the funds should not be used for fellowship or training purposes. Applicants may have received prior or current extramural research funding, but the proposed project should be separate from previous/current funded projects. The proposal must involve a new area of collaboration between at least two cancer center members, including at least one EDT program member. Preference will be given to those proposals that involve research that focuses on translational chemical biology and drug discovery. Projects with strong potential for extramural peer-reviewed funding (e.g. new multi-PI RO1 and/or new PPG) are encouraged. Proposals previously reviewed by a federal funding agency, scored favorably, and now under revision, will be considered (a copy of the summary statement should be enclosed). Additional funding will be available in the second year for those projects in which significant progress has been made and a funding application to the NCI has been submitted or is in preparation.
Final applications are due by March 15, 2011. The body of the proposal should not exceed three pages plus one page for Aims and follow NIH guidelines and formatting. A budget should be included and address the usual categories of personnel, supplies, and equipment (which must be justified). Proposals should not include percent effort (salary) for the Principal Investigator. An electronic copy in PDF format should be submitted and should include:
- Abstract (NIH format; 30 lines)
- Aims (1 page)
- Significance
- Innovation
- Approach
- Budget justification
- NIH biosketch
The Significance, Innovation, and Approach sections should not exceed three pages. Aims page can be up to one page. Abstract should be standard NIH format length (30 lines). Applications will be reviewed by the EDT program leaders and additional expert reviewers as needed. Final funding decisions will be made based on the review evaluations and rankings. All approved projects will undergo mapping via the ITRAC mechanism before dispersing of funds.
Criteria for review are:
- Scientific merit
- Cancer relatedness
- Multidisciplinary and translational nature
- Potential for subsequent peer reviewed funding
What is the timetable?
Completed application: March 15, 2011
Start date: May 1, 2011
A complete application in PDF format should be sent to:
Elizabeth Parsons
Phone: 278-0078
What is ITRAC?
The Indiana University Melvin and Bren Simon Cancer Center Translational Research Acceleration Collaboration (ITRAC) is open to all members/affiliates of the IU Simon Cancer Center and is designed to assist investigators to better position their projects for internal/external grant submission status (eg R21, R01, etc.). If you are a member/affiliate of the IU Simon Cancer Center, please visit the ITRAC Group Site for further details about processes and services.